Dr. Parseghian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2012 - 2015
Tufts University School of MedicineClass of 2012, MD
Certifications & Licensure
CA State Medical License 2014 - Present
FL State Medical License 2021 - Present
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Start of enrollment: 2020 Dec 02
- Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2017 Dec 29
Roles: Contact, Principal Investigator
- Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy Start of enrollment: 2024 Jan 18
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMolecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M Fanaeian, Mark Knafl
JAMA Oncology. 2024-11-01 - Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.Esther J Beck, Alexander D Sherry, Marcus A Florez, Ramez Kouzy, Joseph Abi Jaoude
Cancer Research Communications. 2024-08-01 - Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling.Benny Johnson, Van Morris, Xuemei Wang, Arvind Dasari, Kanwal Raghav
Cancers. 2024-02-09
Lectures
- Circulating tumor DNA (ctDNA) heterogeneity as first- and third-line treatment in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure.2019 ASCO Annual Meeting - 6/1/2019
- Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
The Use of Research Biopsies in Oncology Trials: Challenges and ControversiesMarch 1st, 2019- Open-Label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination with Defactinib (FAK Inhibitor) and Cetuximab in Patients with Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerApril 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
